PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
1.01%
Revenue growth under 50% of CRON.TO's 30.43%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
-129.16%
Negative gross profit growth while CRON.TO is at 28.11%. Joel Greenblatt would examine cost competitiveness or demand decline.
-2648.08%
Negative EBIT growth while CRON.TO is at 1.30%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-2648.08%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-1840.05%
Negative net income growth while CRON.TO stands at 80.33%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-1840.00%
Negative EPS growth while CRON.TO is at 80.37%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-1840.00%
Negative diluted EPS growth while CRON.TO is at 80.37%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
0.63%
Share count expansion well above CRON.TO's 0.04%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
0.63%
Diluted share count expanding well above CRON.TO's 0.04%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-163.79%
Negative OCF growth while CRON.TO is at 98.45%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-178.99%
Negative FCF growth while CRON.TO is at 95.86%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
297.40%
5Y revenue/share CAGR similar to CRON.TO's 297.03%. Walter Schloss might see both companies benefiting from the same mid-term trends.
-52.47%
Negative 3Y CAGR while CRON.TO stands at 100.78%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
-297.77%
Negative 10Y OCF/share CAGR while CRON.TO stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-3403.96%
Negative 5Y OCF/share CAGR while CRON.TO is at 99.13%. Joel Greenblatt would question the firm’s operational model or cost structure.
83.35%
3Y OCF/share CAGR at 75-90% of CRON.TO's 99.39%. Bill Ackman would press for improvements in margin or overhead to catch up.
-51280.40%
Negative 10Y net income/share CAGR while CRON.TO is at 0.00%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-2688.92%
Negative 5Y net income/share CAGR while CRON.TO is 86.28%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-9959.44%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
6257.60%
Equity/share CAGR of 6257.60% while CRON.TO is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
29.59%
Below 50% of CRON.TO's 203.58%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
-12.97%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-12.67%
Firm’s AR is declining while CRON.TO shows 28.61%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-15.83%
Both reduce inventory yoy. Martin Whitman suspects a broader move to lean operations or industry slowdown in demand.
-20.07%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-24.48%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-0.85%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
3.64%
R&D dropping or stable vs. CRON.TO's 12.56%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
-11.81%
We cut SG&A while CRON.TO invests at 2.56%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.